






Proposal to Develop Quantitative Dried Blood Spot (QDBS) Test Kits for Children with Autism

Matt Pamuku, CEO E: <u>matt@sidms.com</u> Ph: 408-472-2333



AIT – Company At-a-Glance

- Co-founder, Prof. Skip Kingston, invented an advanced measurement technology Platform and associated automation tools
 - Privately funded technology company focused on delivering new solutions in many industries
 - Unblemished scientific record and large body of published peer reviewed scientific papers
 - Proven technology: accepted, recognized or adopted in the US (EPA, CDC), Canada (MOE) and many EU countries
 - Codified as a national EPA method and specifically referenced on EPA website: <u>https://www.epa.gov/hw-sw846/sw-846-test-method-6800-elemental-and-</u> <u>molecular-speciated-isotope-dilution-mass</u>
 - Inventor is a world-renowned scientist: <u>https://www.duq.edu/academics/faculty/skip-kingston</u>
 - Patented technology estate globally protected
 - Core measurement technology, SID for the MS has been applied, adopted, recognized, acknowledged in many fields over the past two decades






AIT Solutions - Overarching Value and Benefits


AIT's Patented Next-Generation Mass Spectrometry (MS) Technology Delivers: SID - Definitive, actionable, legally defensible data and zero-falsepositive results with the lowest error margins, and the highest accuracy and precision levels

Thor's Hammer[™] technology boosts level of MS detection by 2 orders of magnitude lower than currently achievable sensitivity & quantitation



<u>SID:</u> Speciated Isotope Dilution (*a patented operating system for the MS*)








Glutathione (GSH): Important Blood Biomarker

- The most abundant blood molecule that has multiple critical functions in human body
- Key detoxifier and a modulator of the body's intra- and extra-cellular metabolic systems
- Unambiguous indicator of immune dysfunction
- The most sought-after biomarker among doctor's wish-list of tests for autism monitoring
- Must test for 2 variants both needed to yield clinically important results
- Impossible with current technologies to do the test and obtain reliable, actionable data

Challenges in GSH Measurement

- GSH Test is a 4-point assay, including
 - Total (GSH-t)
 - Reduced (GSH-r)
 - Oxidized (GSSH)
 - Ratio: GSH/GSSG



- Ratio of the two GSH Measurements is highly informative about patient's health
- Challenge: very low abundance in blood
 - GSH-r is very difficult to measure
 - GSSG is currently impossible to measure because its abundance is 1-2 orders of magnitude lower than GSH (ultra-trace concentration)
- <u>Solution:</u> SID-Quantification with Thor's Hammer

TH(BOOSTER) + SID(OS) = Transformational MS Measurement Platform

- Direct SID Quantification: MS Operating System (OS):
 - Advanced, patented MS quantification technology
 - Patent-pending solution to difficult or many impossible problems in blood testing

• Thor's Hammer

- Is an MS signal booster that increases quantification by 2 orders of magnitude
- Is an invention that has been reduced to practice
- Is a highly selective technology for a targeted biomarker or a group of biomarkers
- Is universally applicable to every sample that can be analyzed in an MS
- Is not a protein molecular modification or chemical derivatization scheme
- Is not a chemical enrichment/amplification manipulation that changes the protein
- Is not an MS-data manipulation algorithm
- Eliminates false positives valuable attribute for clinical testing



SID: Operating system for the MS




Uniquely-enabled Biomarker Tests on QDBS Cards

- Organic biomarkers
 - Glutathione (GSH) Assay for immune system status
 - GSH (Reduced)
 - GSH (Oxidized)
 - GSH (Total)
 - GSH (Ratio: reduced/oxidized)
 - Methylmalonic Acid
 - Vitamin C, Vitamin B12
- Inorganic toxins, toxicants
 - Semi-quantitative scan: 50 metals (toxin burden surveillance)
 - Quantitative tests: Set of 20 electrolytes , immune regulators and other elements of biological significance
- Organic toxins, toxicants
 - Set of 15-20 volatile organic compounds (air pollutants), including forever chemicals, PFOAs and PFAS'


Automated Prototype QDBS System is Fully Operational and Easily Scalable

- 1. Multi-Purpose Sampling (MPS) Arm
- 2. MP Autosampler Card Rack
- 3. Desorption Chamber
- 4. High Pressure Dispenser
- 5. Auto Cartridge Exchanger
- 6. Liquid Chromatograph-MS





This automated prototype QDBS system is being used by Prof. Skip Kingston's Center of Excellence at Duquesne University, Pittsburgh, PA.





Accumulating Data Suggests Environmental Interaction is a Causal Factor

- Emerging Paradigm: Children with autism experience a genotoxic influence from environmental interaction in the womb and after birth
- There are genetic vulnerabilities that impede performance of detoxification functions, such as
 - Heavy metals
 - Chronic exposure to volatile organic pollutants
 - Chemicals that disturbs normal biological processes such as methylation, sulfonation and the immune system
 - Several genotoxic, epigenetic and environmental impacts



Increased Evidence of Toxicity-induced Effects

- Children with autism have a problem of placing methyl and sulfur groups on fat soluble toxic chemicals, upsetting phase 1 and phase 2 detoxification processes
- This problem adversely affects the transformation of toxic chemicals into water-soluble products that can be normally eliminated from the body in urine and handled by the kidneys and liver; subsequently they remain in blood and are sequestered into body tissues
- Early intervention within the critical 3-year window of vulnerability of the developing nervous system is essential to change the trajectory of the spectrum



3-Phase Clinical ASD Program - Summary

- <u>Phase-I (DONE *)</u>: Demonstrated the role of environmental exposure and develop accurate biochemical tests that allow numerical assessment of the children with autism
- <u>Phase-II (DONE Self Funded)</u>: Technologically demonstrated performance of Quantitative Dried Blood Spots that eliminate blood draw with syringe and needle
- Phase-III (PROPOSAL \$3.8 M): Extend all discoveries, QDBS tests in a clinical study to demonstrate clinical utility under a safe, experiential therapy with Dr. Scott Faber's17 years of success; develop, validate and release a QDBS Kit for home blood collection and testing in a central laboratory; automate the entire laboratory workflow



* Funding provided by Heinz Endowments and Richard King Mellon Foundation.

Overview - Scientific/Medical Foundation


- In 2011 a team of multidisciplinary scientists and medical professionals conducted a "<u>Phase-I</u>" double-blind, controlled study focused on Autism
- The team aimed to understand the impact of environmental exposure as a factor in autism progression
- Realizing there were no biomarker tests for autism assessment, the team developed new advanced test that would yield reliable, clinically acceptable and actionable data
- Using these tests, toxins in the blood and hair of children with autism and controls were quantified along with correlations with autism severity
- After the Phase-I study, the Team developed Quantitative Dried Blood Tests (QDBS) to overcome expensive and painful venous blood draw – an insurmountable barrier

Findings and Conclusions of our Phase-I Study


- <u>The most compelling finding</u> of our Phase-I blinded study was the unambiguous identification of a sub-set of autistic children whose improvements were independently revealed by the biomarker tests
- All findings were confirmed at the end of the study when samples were matched with children
- Biochemically established a greater metallothionein dysfunction, chemical detoxification disturbances, immune dysregulation and subsequent loss of immune tolerance
- Unique biomarker tests supported the presence of compensatory physiology in ASD children exposed to higher heavy metal and chemical stress
- Children living in more polluted regions had significantly higher aromatic pollutants, such as benzene, toluene and xylene
- Cumulative concentration of these toxins tracked closely with severity of autism when correlated with the standard ADOS results




Health Impact of Volatile Organic Pollutants Tested in Phase-I Study



Population Comparison of Average Measured Concentration Blood Toxicants Phase-I Study



Percentage of Tested Children in Phase-I Study with Measured Levels of Each Volatile Organic Compound



Knocking Down Barriers to Accessible Testing

- Realized early there were no reliable biochemical tests
 - Invented and developed new, advanced, accurate tests
 - Automated much of the laboratory workflow
 - Published our methods, data and medical findings in peer-reviewed scientific journals, resulting in a dozen papers
- Removed the biggest barrier: blood draw by a phlebotomist
 - Painful, invasive, wasteful, expensive
 - Incredibly difficult to draw blood from autistic children
 - Must be refrigerated, must be packed and shipped in dry-ice
- Developed Quantitative Dried Blood Spots (10-yr effort)
 - Minimally invasive, simple to use, inexpensive
 - Requires only a drop of blood per spot can be collected at home
 - Multiple tests can be done from a single spot
 - Dried blood on DBS cards are not considered bio-hazardous
 - After drop-collection, DBS cards can be sent by regular mail
 - Stored at room temperature and archived for look-back studies
- Regulatory: All tests are CLIA-waived (no FDA approval needed)

Testing with Dried Blood Spot (QDBS) Cards

At-home collection of a single-drop of blood on a QDBS card and sending from anywhere in the world by regular mail



Accuracy MattersSM



THANK YOU

Matt Pamuku, CEO E: <u>matt@sidms.com</u> Ph: 408-472-2333

